Cargando…

Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis

Prepubertal exposure to a pharmacological dose (500 mg kg(−1)) of the phyto-oestrogen genistein can reduce the incidence and multiplicity of carcinogen-induced mammary tumours in rats. However, such an exposure also disrupts the function of the hypothalamic–pituitary–gonadal axis, making it unsuitab...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilakivi-Clarke, L, Onojafe, I, Raygada, M, Cho, E, Skaar, T, Russo, I, Clarke, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363126/
https://www.ncbi.nlm.nih.gov/pubmed/10468283
http://dx.doi.org/10.1038/sj.bjc.6690584
_version_ 1782153626742947840
author Hilakivi-Clarke, L
Onojafe, I
Raygada, M
Cho, E
Skaar, T
Russo, I
Clarke, R
author_facet Hilakivi-Clarke, L
Onojafe, I
Raygada, M
Cho, E
Skaar, T
Russo, I
Clarke, R
author_sort Hilakivi-Clarke, L
collection PubMed
description Prepubertal exposure to a pharmacological dose (500 mg kg(−1)) of the phyto-oestrogen genistein can reduce the incidence and multiplicity of carcinogen-induced mammary tumours in rats. However, such an exposure also disrupts the function of the hypothalamic–pituitary–gonadal axis, making it unsuitable for breast cancer prevention. We studied whether prepubertal exposure to genistein at a total body dose broadly comparable to the level typical of Oriental countries, approximately 1 mg kg(−1) body weight, affects mammary tumorigenesis. We also studied whether prepubertal exposure to zearalenone, a major source for phyto-oestrogens in the USA, influences breast cancer risk. Prepubertal rats were treated between postnatal days 7 and 20, with 20 μg (~ 1 mg kg(−1) body weight) of either genistein or zearalenone. Zearalenone exposure significantly reduced both the incidence and multiplicity of mammary tumours induced by 7,12-dimethylbenz(a)anthracene (DMBA). Genistein exposure significantly reduced tumour multiplicity, but not tumour incidence, when compared with vehicle-treated animals. Furthermore, 60% of the tumours in the genistein group were not malignant, while all the tumours analysed for histopathology in the vehicle and zearalenone groups were adenocarcinomas. A higher number of differentiated alveolar buds, and lower number of terminal ducts, were present in the DMBA-treated mammary glands of the phyto-oestrogen exposed rats. The concentration of oestrogen receptor (ER) binding sites after the DMBA treatment was low in the mammary glands of all groups but a significantly higher proportion of the glands in the zearalenone exposed rats were ER-positive (i.e. ER levels ≥ 5 fmol mg(−1) protein) than the glands of the vehicle controls. Our data suggest that a prepubertal exposure to a low dose of either zearalenone or genistein may protect the mammary gland from carcinogen-induced malignant transformation, possibly by increasing differentiation of the mammary epithelial tree. © 1999 Cancer Research Campaign
format Text
id pubmed-2363126
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23631262009-09-10 Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis Hilakivi-Clarke, L Onojafe, I Raygada, M Cho, E Skaar, T Russo, I Clarke, R Br J Cancer Regular Article Prepubertal exposure to a pharmacological dose (500 mg kg(−1)) of the phyto-oestrogen genistein can reduce the incidence and multiplicity of carcinogen-induced mammary tumours in rats. However, such an exposure also disrupts the function of the hypothalamic–pituitary–gonadal axis, making it unsuitable for breast cancer prevention. We studied whether prepubertal exposure to genistein at a total body dose broadly comparable to the level typical of Oriental countries, approximately 1 mg kg(−1) body weight, affects mammary tumorigenesis. We also studied whether prepubertal exposure to zearalenone, a major source for phyto-oestrogens in the USA, influences breast cancer risk. Prepubertal rats were treated between postnatal days 7 and 20, with 20 μg (~ 1 mg kg(−1) body weight) of either genistein or zearalenone. Zearalenone exposure significantly reduced both the incidence and multiplicity of mammary tumours induced by 7,12-dimethylbenz(a)anthracene (DMBA). Genistein exposure significantly reduced tumour multiplicity, but not tumour incidence, when compared with vehicle-treated animals. Furthermore, 60% of the tumours in the genistein group were not malignant, while all the tumours analysed for histopathology in the vehicle and zearalenone groups were adenocarcinomas. A higher number of differentiated alveolar buds, and lower number of terminal ducts, were present in the DMBA-treated mammary glands of the phyto-oestrogen exposed rats. The concentration of oestrogen receptor (ER) binding sites after the DMBA treatment was low in the mammary glands of all groups but a significantly higher proportion of the glands in the zearalenone exposed rats were ER-positive (i.e. ER levels ≥ 5 fmol mg(−1) protein) than the glands of the vehicle controls. Our data suggest that a prepubertal exposure to a low dose of either zearalenone or genistein may protect the mammary gland from carcinogen-induced malignant transformation, possibly by increasing differentiation of the mammary epithelial tree. © 1999 Cancer Research Campaign Nature Publishing Group 1999-08 /pmc/articles/PMC2363126/ /pubmed/10468283 http://dx.doi.org/10.1038/sj.bjc.6690584 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Hilakivi-Clarke, L
Onojafe, I
Raygada, M
Cho, E
Skaar, T
Russo, I
Clarke, R
Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis
title Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis
title_full Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis
title_fullStr Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis
title_full_unstemmed Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis
title_short Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis
title_sort prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363126/
https://www.ncbi.nlm.nih.gov/pubmed/10468283
http://dx.doi.org/10.1038/sj.bjc.6690584
work_keys_str_mv AT hilakiviclarkel prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis
AT onojafei prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis
AT raygadam prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis
AT choe prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis
AT skaart prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis
AT russoi prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis
AT clarker prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis